Europe Transdermal Medical Patch Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Single Layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Vapor Patch, and Matrix), Application (Neurologic Conditions, Pain Manageme

Europe Transdermal Medical Patch Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Single Layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Vapor Patch, and Matrix), Application (Neurologic Conditions, Pain Management, Nicotine Cessation, Cardiovascular Disorders, Hormonal Therapy, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

The Europe transdermal medical patch market is expected to grow from US$ 2,434.09 million in 2023 to US$ 3,079.58 million by 2028. It is estimated to register a CAGR of 4.8% from 2023 to 2028.

Increasing Prevalence of Chronic Diseases Fuels Europe Transdermal Medical Patch Market

Transdermal medical patches are used to administer medications to people suffering from chronic diseases such as heart disease, stroke, diabetes, cancer, obesity, and arthritis.

A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently showed promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. It works by relaxing the blood vessels and reducing the stress on the heart, thereby lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.

Rivastigmine patch is used to treat dementia (memory loss) associated with mild, moderate, or severe Alzheimer's disease or mild-to-moderate dementia associated with Parkinson's disease. Rivastigmine and donepezil, which are cholinesterase inhibitors, exhibit a dose–response relationship, with higher doses of the drugs demonstrating greater efficacy. As a small, lipophilic, and hydrophilic molecule, rivastigmine is chemically well-suited for transdermal delivery. The technology underlying the rivastigmine patch contributes to its discreetly small and thin appearance. Thus, the rivastigmine patch enables quick and easy access to high-dose efficacy.

Therefore, the increasing prevalence of chronic diseases catalyzes the demand for medical patches.

Europe Transdermal Medical Patch Market Overview

The Europe transdermal medical patch market is segmented into the UK, Germany, Spain, Italy, and the Rest of Europe. In 2022, the UK held the largest share of the Europe transdermal medical patch market. The rising number of patients suffering from chronic conditions and viral diseases and increasing activities in research and development are the key factors propelling the market for transdermal medical patches. Also, the growing prevalence of chronic diseases are favoring market expansion.

Europe Transdermal Medical Patch Market Revenue and Forecast to 2028 (US$ Million)

Europe Transdermal Medical Patch Market Segmentation

The Europe transdermal medical patch market is segmented into type, application, distribution channel, and country.

Based on type, the market is segmented into single-layer drug in-adhesive, multi-layer drug in-adhesive, reservoir, vapor patch and matrix. The matrix segment registered the largest market share in 2023.

Based on application, the Europe transdermal medical patch market is segmented into neurologic conditions, pain management, nicotine cessation, cardiovascular disorders, hormonal therapy, and others. The pain management segment held the largest market share in 2023.

Based on distribution channel, the Europe transdermal medical patch market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2023.

Based on country, the Europe transdermal medical patch market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the market share in 2023.

Boehringer Ingelheim International GmbH, Endo International Inc, Hisamitsu Pharmaceutical Co Inc, Johnsons and Johnsons, Medline Industries LP, Novartis AG, Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc are the leading companies operating in the transdermal medical patch market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe transdermal medical patch market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe transdermal medical patch market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the transdermal medical patch market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution